Claritev Corporation (NYSE:CTEV) FY Conference December 04, 2025 08:00 AM ET Company ParticipantsDoug Garis - CFOTravis Dalton - President and CEOConference Call ParticipantsJess Tassin - AnalystJess TassinHi, everyone. Thanks so much for joining. My name's Jess Tassin. I cover managed care and healthcare IT at Piper. I'm really excited to be here with Claritev Management this morning. We've got CEO Travis Dalton and CFO Doug Garis on stage with me. Travis and Doug, thank you guys so much for being here.Tra ...

Financial Data and Key Metrics Changes - For Q3 2025, total revenue was $196 million, an increase of approximately $1 million compared to the prior year [20] - Prescription transaction revenue decreased by 9% year-over-year, primarily due to the impact of Rite Aid store closures and lower transaction volume in the integrated savings program [21] - Adjusted EBITDA for the quarter was $66.3 million, reflecting a 2% increase year-over-year and an adjusted EBITDA margin of 33.8%, which is an improvement of 50 basis points compared to the prior year [22] Business Line Data and Key Metrics Changes - Manufacturer solutions revenue grew by 54% year-over-year to $43.4 million, driven by strong execution and expansion across new and existing brand partnerships [21][11] - The company has over 200 brand affordability programs on its platform, with nearly 80 offering cash prices [13] Market Data and Key Metrics Changes - The ongoing changes in the U.S. healthcare environment, particularly around prescription drug pricing, are seen as a significant opportunity for GoodRx, especially with the introduction of Trump Rx and the focus on price transparency [6][9] - The company is positioned to benefit from the anticipated increase in uninsured individuals and higher out-of-pocket costs due to changes in the Affordable Care Act marketplace subsidies and Medicaid support [9] Company Strategy and Development Direction - GoodRx is focused on expanding partnerships with pharmaceutical manufacturers and retail pharmacies to enhance access and affordability for consumers [19] - The company is investing in its manufacturer solutions capabilities and aims to deliver a true end-to-end e-commerce model to the pharmaceutical industry [14] - The new brand campaign, "The Savings Wrangler," aims to reinforce GoodRx's position as a trusted name in prescription savings and has already shown positive results in key marketing metrics [18] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the broader healthcare environment's challenges but remains confident in GoodRx's ability to navigate these changes and capitalize on emerging opportunities [10][25] - The company expects continued growth in its manufacturer solutions segment, projecting approximately 35% revenue growth in 2025 [24] - Management is optimistic about the long-term growth potential as the market shifts towards greater price transparency and consumer-direct models [9][26] Other Important Information - The company repurchased approximately 13.4 million shares at an average price of $4.61 per share, totaling $61.6 million, with about $81.4 million remaining under its share repurchase program [22] - GoodRx is actively engaged with the administration and HHS to inform policy efforts that expand access and affordability for all Americans [6] Q&A Session Summary Question: Can you discuss the stabilizing PTR environment and its implications for GoodRx? - Management noted that 2025 has been challenging due to various macro conditions but anticipates a return to growth in 2026 as more people may become uninsured, creating a tailwind for GoodRx [30][31] Question: How does GoodRx differentiate itself in the manufacturer solutions space? - GoodRx highlighted its position as the number one digital prescription marketplace, providing manufacturers with significant ROI and access to a large consumer base [33] Question: What are the implications of PBMs moving towards point-of-sale discounts? - Management expressed support for this shift, indicating that it aligns with GoodRx's mission of enhancing affordability for consumers at the pharmacy counter [36][37] Question: How will GoodRx integrate with Trump Rx? - GoodRx is actively working with HHS to integrate its pricing into the Trump Rx platform, positioning itself as a key provider of pricing information [39][41] Question: What is the outlook for the ISP relationship and potential new products? - Management indicated that while the ISP relationship has evolved, there remains potential for new product offerings that could enhance affordability for consumers [43][44]

Healthcare Industry Trends - Patient visits have increased by an average of 1-2% annually over the past 40 years, with a higher increase of about 4% in the last two years [5] - Telehealth interactions and other virtual interactions are included in the utilization metrics, not just physical patient visits [6] - UnitedHealth is experiencing challenges due to higher utilization and costs [1] Waystar's AI Solutions - Waystar utilizes AI to address higher utilization with more efficiency, helping clients get paid accurately, efficiently, and fully [3] - Waystar's AI automates low complexity, high volume tasks, returning more time to providers and improving accuracy and efficiency [5][6] - Waystar's software helps providers understand a patient's financial situation and automatically creates accurate claims [7] - Waystar's AI-powered platform processes over 6 billion insurance transactions annually, constituting more than $18 trillion of insurance gross claim charges [9] - Waystar's platform enables providers to interact with patients and help them understand their financial responsibility before receiving care [10] Transparency and ROI - Waystar helps patients understand their financial responsibility, offering more transparency than historically available [9][10] - Waystar is creating a real ROI for the providers they work with [7][12] - Waystar advocates for both providers and patients, bringing simplicity and common understanding to pricing [11]

Core Insights - The article discusses various studies related to healthcare economics, focusing on cost transparency, mental health trends, and the impact of social factors on healthcare utilization and outcomes. Group 1: Healthcare Costs - The gradual disclosure of medical procedure prices on a government website led to a decrease in negotiated prices for surgical and radiology procedures by 5.1% and 9.1% respectively, primarily driven by provider-insurer negotiations rather than patient price shopping [9][11] - When primary care physicians (PCPs) are informed about specialist costs, referrals to lower-cost specialists increase by 4.6 percentage points for each rank reduction in costliness, potentially reducing referral costs by 45% in the short term [19][21] - A study on the Female Secondary School Stipend Program in Bangladesh found that it improved full immunization rates by 4.2 percentage points among children of mothers who received stipends for five years [39][40] Group 2: Mental Health - Worsening mental health has contributed to rising mortality rates among certain demographic groups, particularly non-Hispanic Whites, accounting for 9% to 29% of the increase in mortality rates [26][28][29] - Access to high-speed internet has been linked to increased mental health diagnoses and a rise in adolescent suicide rates, especially among girls [30][31] Group 3: Healthcare Demand - Non-clinical factors, such as living alone, significantly affect the length of hospital stays, particularly for elderly patients in public hospitals [36][37] - Rural populations exhibit a higher incidence of depression, with 33% to 39% of the rural-urban difference explained by factors such as income, education, and geographic region [33][34] Group 4: Neonatal Care - Advances in neonatal care have improved survival rates for high-risk newborns, but moderate-risk infants admitted to lower capability units received more intensive care, leading to reduced healthcare use post-discharge [16][18]